GlassScriptPhysician profile
Diaa Osman
NPI 1689894495
$2,871.21
in general payments reported to CMS, 2019-2025
16 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $45.45 · 2023: $51.76 · 2024: $385 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,200 · Food and Beverage: $597 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,200.00 |
| Food and Beverage | $596.82 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,405.70 | 2025 | Tagrisso, Calquence |
| Incyte Corporation | $825.00 | 2025 | Monjuvi |
| Tempus Ai, INC | $147.28 | 2024 | |
| Intera Oncology, INC | $106.78 | 2024 | Intera |
| Glaxosmithkline, LLC. | $93.53 | 2025 | Ojjaara, Blenrep, Jemperli |
| Daiichi Sankyo INC. | $67.66 | 2024 | Vanflyta |
| Novartis Pharmaceuticals Corporation | $53.02 | 2022-2023 | |
| Stemline Therapeutics INC. | $27.14 | 2024 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $22.20 | 2022 | |
| Pfizer INC. | $21.99 | 2023 | |
| Janssen Biotech, INC. | $21.78 | 2025 | Tecvayli |
| Genentech USA, INC. | $19.14 | 2024 | Lunsumio, Polivy, Rozlytrek |
| Genzyme Corporation | $17.23 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Celgene Corporation | $13.82 | 2025 | Reblozyl |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diaa Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.